Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Effect of SURGICEL® Powder in TKA
Sponsor: Peking University Third Hospital
Summary
The study subjects are patients in our hospital's orthopedics department undergoing unilateral primary total knee arthroplasty (TKA) due to primary osteoarthritis. Through a prospective, parallel randomized controlled study, 112 participants will be divided into two groups: the SURGICEL® Powder group and the non-use group. The study will compare the total perioperative blood loss , intraoperative blood loss, transfusion rate and volume, postoperative hemoglobin decline, hematocrit decline, limb swelling rate , postoperative limb pain , and range of motion. Statistical analysis will be performed on the data to observe the hemostatic effects of SURGICEL® Powder, providing recommendations for the clinical use of SURGICEL® Powder.
Official title: Evaluation of the Safety and Hemostatic Effectiveness of SURGICEL® Powder in TKA:a Randomized Controlled Trial
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
112
Start Date
2024-09-28
Completion Date
2025-09
Last Updated
2025-02-12
Healthy Volunteers
No
Conditions
Interventions
SURGICEL® Powder
SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
Locations (1)
Peking University Third Hospital
Beijing, Beijing Municipality, China